Trazodone has been reported to inhibit the PERK–eIF2α signaling pathway, which is overactivated in Alzheimer’s disease and contributes to abnormal amyloid precursor protein (APP) translation and Aβ accumulation (Halliday et al., 2015); (Rohe et al., 2009). This evidence concerns the gene EIF2AK3 and Alzheimer disease.